TMB-001 for Ichthyosis

Dr. Chih-ho Hong Medical Inc., Surrey, Canada
IchthyosisTMB-001 - Drug
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial is testing a topical ointment for the treatment of chronic idiopathic urticaria (CIU). The trial is designed to test the safety and efficacy of the ointment, and will enroll subjects with either the RXLI or ARCI subtypes of CIU. The trial will be conducted in three periods: induction (3 weeks), treatment (9 weeks), and maintenance (12 weeks).

Eligible Conditions
  • Ichthyosis

Treatment Effectiveness

Phase-Based Effectiveness

2 of 3
Phase 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 12 weeks

12 weeks
Change in Investigator global assessment (IGA) score
Change in Visual Index of Ichthyosis Severity score
To investigate the proportion of subjects experiencing local skin reactions with topically applied TMB-001 0.05% ointment.

Trial Safety

Phase-Based Safety

3 of 3
This is further along than 85% of similar trials

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3 Treatment Groups

TMB-001 0.05%
1 of 3
Maximal use
1 of 3
1 of 3

Experimental Treatment

Non-Treatment Group

142 Total Participants · 3 Treatment Groups

Primary Treatment: TMB-001 · Has Placebo Group · Phase 3

TMB-001 0.05%
Experimental Group · 1 Intervention: TMB-001 · Intervention Types: Drug
Maximal use
Experimental Group · 1 Intervention: TMB-001 · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Matching Vehicle · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks

Who is running the clinical trial?

Timber Pharmceuticals LLCLead Sponsor
1 Previous Clinical Trials
34 Total Patients Enrolled
1 Trials studying Ichthyosis
34 Patients Enrolled for Ichthyosis

Eligibility Criteria

Age Any Age · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a disease in your upper back, upper arm, lower leg, or dorsal foot.

Who else is applying?

What state do they live in?
North Carolina100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%
Why did patients apply to this trial?
  • "I need help managing my HS."
How many prior treatments have patients received?

Frequently Asked Questions

How many people will be taking part in this study at the most?

"One hundred and forty-two individuals that fit the pre-stated inclusion criteria are required to enroll in this clinical trial. US Derm Partners in Phoenix, Arizona and Stanford Children's Health in Palo Alto, California are two of the medical sites where patients can participate in this study." - Anonymous Online Contributor

Unverified Answer

Are there any side effects to taking TMB-001?

"TMB-001 has been given a safety score of 3 by our team at Power. This is because it is a Phase 3 trial, which demonstrates some efficacy and multiple rounds of data supporting safety." - Anonymous Online Contributor

Unverified Answer

In how many places is this research being done?

"This clinical trial is being conducted at 18 different sites, including Stanford Children's Health in Palo Alto, Medical Dermatology Specialists (US Derm Partners) in Phoenix, and About Skin Dermatology in Centennial, among other locations." - Anonymous Online Contributor

Unverified Answer

Are there any unfilled positions in this experiment?

"The trial is definitely still recruiting patients if you refer to the information on To be more specific, the trial was first posted on June 21st, 2022 and was edited more recently on July 6th, 2022. In total, the study needs 142 patients from 18 different locations." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.